Phase 2B Multi-center, Open Label, Safety and Efficacy Study of VGT-309 in Subjects With Cancer in the Lung.

Phase 2B Multi-center, Open Label, Safety and Efficacy Study of VGT-309 in Subjects With Cancer in the Lung.
Conditions: Lung Cancer; Lung Metastases

Interventions: Drug: VGT-309

Sponsors: Vergent Bioscience, Inc.

**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

November 23, 2023Comments OffClinicalTrials.gov | Oncology Clinical Trials | Oncology Studies | US National Library of Medicine
Comments